common glp 1 agonists GLP-1 For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Frontiers | GLP-1 Receptor Agonists:

Experimental studies demonstrated that modulation of NNMT pathways could influence metabolic signaling networks involved in cellular energy utilization and body composition regulation

Evidence from RCTs has shown that the benefits of each agent are maintained regardless of concomitant use [118,119], without a significant increase in the risk of hypoglycemia or AKI [120,121]

They target different pathways: NAD+ restoration via NMN and free radical neutralisation via glutathione

In clinical use, it may be prescribed by healthcare professionals to help manage conditions linked to oxidative damage or to support recovery where antioxidant levels are reduced

Salscheider, S